Trial
NCT04230304
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Mayo Clinic
Collaborators
—
Condition
Recurrent Chronic Lymphocytic Leukemia
Intervention
Daratumumab
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-30